3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
10
Phase 1
3
Phase 1/2
2
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
20
Gastrointestinal Stromal Tumors
9
Kidney Neoplasms
6
Breast Neoplasms
4
Neoplasms
3
Neoplasm Metastasis
3
Kidney Diseases
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Urologic Neoplasms
1
Prostatic Neoplasms
1
Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1
1
Patient Preference
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Gastrointestinal Neoplasms
1
Gastro-enteropancreatic neuroendocrine tumor
1
Colorectal Neoplasms
1
Carcinoma, Islet Cell
1
Carcinoma, Hepatocellular
1
Carcinoid Tumor
1
Advanced Renal Cancer
1
Adenoma, Islet Cell
1
Interventions
Prednisone
53
Radiotherapy
52
Docetaxel
51
Leuprolide
48
Goserelin
47
bicalutamide
45
enzalutamide
28
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
27
Androgen Antagonists
27
Flutamide
24
Triptorelin Pamoate
22
apalutamide
18
Gonadotropin-Releasing Hormone
18
Abiraterone Acetate
17
Radiation
15
abiraterone
14
Zoledronic Acid
14
Magnetic Resonance Spectroscopy
13
gallium 68 PSMA-11
12
Prednisolone
11
luprolide acetate gel depot
10
darolutamide
9
Radiosurgery
9
cabazitaxel
8
Standard of Care
8
Specimen Handling
8
Radiotherapy, Intensity-Modulated
8
Radiotherapy, Conformal
8
Estramustine
8
Dexamethasone
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Prostatic Neoplasms
×
Sunitinib
×
Clear all
NCT00676650
2013-03-08
SUN 1120
Pfizer
Phase 3
Terminated
873 enrolled
10 charts